Abstract:BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC), and TERT promoter (TERTp) mutation is strongly associated with cancer-related mortality. However, predictive power of the two mutations remains inconclusive. We aimed to verify the prognostic effects of both mutations to assess the value of mutation detection for risk stratification in terms of PTC prognosis and tumour invasion, to guide PTC diagnosis and treatment. We conducted a literature search in the MEDLINE (PubMed), EMBASE, Web of Science and CENTRAL (Cochrane library) databases, from inception to February 2020. Basic characteristics, prognoses and clinicopathological features were collected from the included studies for further analysis. Twelve studies involving 4184 PTC patients were enrolled in our analysis. In total, 2412 (57.6%) of the patients carried either BRAFV600E or TERTp mutation, and 290 (6.9%) patients had both mutations. TERTp mutation was more common in patients with BRAFV600E mutation (RR = 1.75 [95% CI 1.44-2.13]). Patients with both mutations had a worse prognosis compared with those with a single mutation (vs BRAFV600E only: RR = 5.34 [4.20-6.78] vs TERTp only: RR = 2.12 [1.41-3.19]). TERTp mutation alone independently increased the risk of a poor prognosis (RR = 2.90 [1.93-4.35]) in terms of mortality (RR = 15.09 [7.75-29.37]), disease persistence (RR = 4.00 [2.03-7.90]), recurrence (RR = 4.34 [4.20-6.78]), lymph node metastasis (RR = 1.57 [1.24-1.99]) and distant metastasis (RR = 2.94 [1.13-7.65]). We found that PTC patients with BRAFV600E mutation were more likely to have TERTp mutation. TERTp mutation was an independent predictive factor for poor prognosis of PTC patients, but the predictive value of BRAFV600E mutation remains inconclusive. Patients with both mutations have remarkably higher risks of adverse outcomes compared with those with a single mutation. PTC patients could benefit from mutation detection for aiding risk stratification (BRAF + TERT+ > BRAF - TERT+ > BRAF + TERT-).

Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.

Clinicopathological Significance of TERT Promoter Mutation in Papillary Thyroid Carcinomas: a Systematic Review and Meta‐analysis

Association of Telomerase Reverse Transcriptase Promoter Mutations with Clinicopathological Features and Prognosis of Thyroid Cancer: a Meta-Analysis.

TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis

Suspicious Ultrasound and Clinicopathological Features of Papillary Thyroid Carcinoma Predict the Status of TERT Promoter

The Role of TERT Promoter Mutations in Postoperative and Preoperative Diagnosis and Prognosis in Thyroid Cancer.

Clinical Characteristics And Prognostic Significance Of Tert Promoter Mutations In Cancer: A Cohort Study And A Meta-Analysis

Clinical features combined with ultrasound characteristics to predict TERT promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years

TERT promoter methylation is associated with high expression of TERT and poor prognosis in papillary thyroid cancer

Promoter mutation-independent TERT expression is related to immune-enriched milieu in papillary thyroid cancer

TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer.

TERTPromoter Mutations and Their Association Withbrafv600e Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

The Predictive Value Of Coexisting Brafv600e And Tert Promoter Mutations On Poor Outcomes And High Tumour Aggressiveness In Papillary Thyroid Carcinoma: A Systematic Review And Meta-Analysis

Coexisting RET/PTC and TERT Promoter Mutation Predict Poor Prognosis but Effective RET and MEK Targeting in Thyroid Cancer

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas

Telomerase Reverse Transcriptase Mutations Are Independent Predictor Of Disease-Free Survival In Middle Eastern Papillary Thyroid Cancer

TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance

TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

Clinical and Histopathological Features of Thyroid Cancer with TERT Promoter Molecular Alterations in Isolation Versus with Concurrent Molecular Alterations: A Multicenter Retrospective Study

P-150 * RECURRENT TELOMERASE REVERSE TRANSCRIPTASE PROMOTER MUTATIONS IN NON-SMALL-CELL LUNG CANCERS